These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38805213)

  • 1. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
    Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
    J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TYK2: an emerging therapeutic target in rheumatic disease.
    Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
    Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
    Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.
    Du SS; Fang YQ; Zhang W; Rao GW
    Curr Med Chem; 2024; 31(20):2900-2920. PubMed ID: 38904160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
    Fang Z; Sun H; Wang Y; Sun Z; Yin M
    Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
    Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
    Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
    Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
    Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
    Liu C; Lin J; Langevine C; Smith D; Li J; Tokarski JS; Khan J; Ruzanov M; Strnad J; Zupa-Fernandez A; Cheng L; Gillooly KM; Shuster D; Zhang Y; Thankappan A; McIntyre KW; Chaudhry C; Elzinga PA; Chiney M; Chimalakonda A; Lombardo LJ; Macor JE; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2021 Jan; 64(1):677-694. PubMed ID: 33370104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
    Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
    Muromoto R; Shimoda K; Oritani K; Matsuda T
    Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
    Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
    Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.
    Gerstenberger BS; Banker ME; Clark JD; Dowty ME; Fensome A; Gifford R; Griffor MC; Hegen M; Hollingshead BD; Knafels JD; Lin TH; Smith JF; Vajdos FF
    Sci Rep; 2020 Jun; 10(1):8974. PubMed ID: 32488071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
    Nogueira M; Puig L; Torres T
    Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.